Department of Psychology, University of Rhode Island, Kingston, Rhode Island, USA.
J Child Adolesc Psychopharmacol. 2023 Jun;33(5):164-175. doi: 10.1089/cap.2022.0090. Epub 2023 May 30.
Childhood mental illness is an ongoing public health crisis which is accompanied by an increase in antidepressant (i.e., serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors) use in children. Recent evidence highlighting the cultural differences in the utilization, efficacy, and tolerability of antidepressants in children underscores the need for diverse samples in studies examining antidepressant use. Furthermore, the American Psychological Association in recent years has emphasized the importance of including participants from diverse backgrounds in research studies, including investigations of medication efficacy. The present study, therefore, examined the demographic composition of samples used and reported in antidepressant efficacy and tolerability studies with children and adolescents experiencing anxiety and/or depression in the last decade. A systematic literature review utilizing two databases was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In line with the extant literature, antidepressants were operationalized as , , , , and Out of the 11 articles included in this review, 71% reported having a primarily adolescent sample (i.e., over 50% of the sample was 12 years or older). In addition, studies omitted any transgender, genderqueer, or gender-nonconforming demographics, and one study omitted all racial demographic information. While 64% of studies only partially reported racial demographic information, 36% of studies omitted ethnicity demographics altogether. The present study addresses a gap in the literature by supporting a lack of diversity in studies examining antidepressant use in children and adolescents. Furthermore, it underscores the importance of future studies using a more diverse and representative sample. Limitations of the present study included limited generalizability and the lack of independent and blind reviewer process. Possible explanations for the lack of inclusion and suggestions on how to address these disparities are discussed.
儿童精神疾病是一场持续的公共卫生危机,伴随着儿童抗抑郁药(即选择性 5-羟色胺再摄取抑制剂和 5-羟色胺-去甲肾上腺素再摄取抑制剂)使用的增加。最近的证据强调了在儿童中使用、疗效和耐受性方面文化差异的重要性,突显了在研究抗抑郁药使用时需要多样化样本的必要性。此外,近年来美国心理协会强调了在研究中包括来自不同背景的参与者的重要性,包括对药物疗效的研究。因此,本研究检查了过去十年中研究儿童和青少年焦虑和/或抑郁时抗抑郁药疗效和耐受性研究中使用和报告的样本的人口统计学构成。本研究按照系统评价和荟萃分析的首选报告项目(PRISMA)指南,利用两个数据库进行了系统文献综述。与现有文献一致,将抗抑郁药定义为 、 、 、 、 。在纳入本综述的 11 篇文章中,71%的文章报告了主要是青少年样本(即,超过 50%的样本为 12 岁或以上)。此外,有 研究排除了任何跨性别、性别酷儿或非性别认同的人口统计学数据,一项研究排除了所有种族人口统计学信息。虽然 64%的研究仅部分报告了种族人口统计学信息,但 36%的研究完全排除了种族人口统计学信息。本研究通过支持在研究儿童和青少年抗抑郁药使用时缺乏多样性来解决文献中的空白。此外,它强调了未来研究使用更具多样性和代表性样本的重要性。本研究的局限性包括有限的普遍性以及缺乏独立和盲审过程。讨论了缺乏纳入的可能解释以及解决这些差异的建议。